REG - Hikma Pharmaceutical - Notice of GM

Hikma PharmaceuticalsAnnouncement

25/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220425:nRSY1042Ja&default-theme=true

RNS Number : 1042J  Hikma Pharmaceuticals Plc  25 April 2022

FOR IMMEDIATE RELEASE

Hikma Pharmaceuticals PLC

25 April 2022

HIKMA PHARMACEUTICALS PLC

AGM UPDATE AND PUBLICATION OF EGM NOTICE

Withdrawal of 2022 AGM Resolution 15

The Board of Hikma Pharmaceuticals PLC ("Hikma" or the "Company") today
announces that it has decided to withdraw Resolution 15 from the agenda of the
Annual General Meeting ("2022 AGM") of the Company's shareholders to be held
at 1.00 p.m. (London time) today, 25 April 2022.

Resolution 15, as set out in the notice of the 2022 AGM (the "2022 AGM
Notice"), proposes the creation of distributable reserves in the capital of
the Company by means of a bonus issue and a Court-sanctioned capital reduction
(the "Relevant Business"). At the 2022 AGM, Resolution 15 will be withdrawn
from the business of the meeting on account of a typographical error which
resulted in Resolution 15 being incorrectly proposed as an ordinary
resolution, rather than a special resolution, and consequently being of no
legal effect.

Save as set out above, the 2022 AGM will proceed as planned later today in
accordance with the arrangements previously notified. The withdrawal of
Resolution 15 does not otherwise affect the validity of the 2022 AGM Notice,
the proxy form or any proxy votes already submitted on other proposed
resolutions. The numbering of all other proposed resolutions at the 2022 AGM
will remain unchanged.

Publication of EGM Notice

In order to allow the Relevant Business to be properly considered by
shareholders, the Company is today calling a separate general meeting of its
shareholders to be held at 10 a.m. on 20 May 2022 at Hikma Offices, 5th Floor,
1 New Burlington Place, London W1S 2HR, United Kingdom (the "EGM").  The
special resolution relating to the Relevant Business will be the single item
of business at the EGM. Except to correct the typographical error in
connection with Resolution 15 of the 2022 AGM Notice, there will be no changes
to the text of the resolution or the accompanying explanatory note, each as
originally contained in the 2022 AGM Notice.

Notice of the EGM will today be published and posted to those shareholders on
the Company's register of members as at the close of business on 21 April 2022
who have elected to receive paper communications. In compliance with the UK
Financial Conduct Authority's Listing Rules, the notice of EGM will shortly be
submitted to, and available for inspection from, the National Storage
Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

Full details of the business of, and arrangements for, the EGM (including
voting procedures) are contained in the notice of the EGM. This announcement
is not a substitute for reading the notice of the EGM in full.

Peter Speirs

Company Secretary

For and on behalf of

Hikma Pharmaceuticals PLC

25 April 2022

 

Enquiries

 Peter Speirs        +44 (0)20 7399 2772

Company Secretary

 

About Hikma

Hikma helps put better health within reach every day for millions of people
around the world. For more than 40 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
the United States (US), the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform cutting-edge science
into innovative solutions that transform people's lives. We're committed to
our customers, and the people they care for, and by thinking creatively and
acting practically, we provide them with a broad range of branded and
non-branded generic medicines. Together, our 8,700 colleagues are helping to
shape a healthier world that enriches all our communities. We are a leading
licensing partner, and through our venture capital arm, are helping bring
innovative health technologies to people around the world. For more
information, please visit: www.hikma.com (http://www.hikma.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGBKBBDPBKDOQB